This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| ASTRAZENECA PLC | 8,511.0 | 6.9% |
| AVAST PLC | 500.0 | 6.3% |
| OCADO GROUP PLC | 2,561.0 | 5.4% |
| NEXT PLC | 6,092.0 | 5.2% |
| AUTO TRADER GROUP PLC | 594.4 | 4.7% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| STANDARD CHARTERED PLC | 354.9 | -4.7% |
| CRH PLC | 2820.0 | -4.4% |
| HSBC HOLDINGS PLC | 332.5 | -4.2% |
| BARCLAYS PLC | 110.4 | -2.6% |
| LLOYDS BANKING GROUP PLC | 28.5 | -2.5% |
| Major World Indices | Price | % Chg | 1 YEAR |
| UK 100 INDEX | 5,883 | 1.7% | -20.4% |
| DOW JONES INDUS. AVG | 27,848 | 1.3% | 1.3% |
| DAX INDEX | 12,324 | 2.0% | -6.3% |
| NIKKEI 225 | 24,105 | 1.7% | 3.7% |
| S&P/ASX 200 INDEX | 6,140 | 1.3% | -8.3% |
| Commodities | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 38.52 | -1.61% |
| Brent Crude (ICE) | USD/bbl. | 40.58 | -1.58% |
| Gold Spot | USD/t oz. | 1,912 | 0.5% |
| Copper (Comex) | USd/lb. | 310 | -0.3% |
Click graph to enlarge
UK 100 called to open +22 points this morning at 5905. Calls for a positive open come as The Bank of England has left interest rates unchanged at 0.1 percent and expanded its quantitative easing programme to boost the economy by another £150billion to £875billion. This is as America remains in a tense political limbo, with vote counting continuing in five key undeclared states. In Asia, Japan’s Nikkei traded up 410 points or 1.73% at 24,105 whilst Hong Kong’s Hang Seng rose by 2.65% to 25,545. Stateside yesterday saw vast market fluctuation, culminating in, the Dow Jones closed 367 points or 1.34% higher, at 27,847, whilst the S&P 500 marked a 2.2% rise to finish the session at 3,443. The Nasdaq, meanwhile, climbed further adding 3.85% to end Wednesday at 3.85%. The small-cap focussed Russel 2000 index was more muted, finishing the day at 1,615.
AstraZeneca beat Q3 sales estimates as demand for its diverse portfolio of drugs remained strong during COVID-19 pandemic lockdowns, and it maintained its 2020 forecasts. They reiterated that they expect results from their late-stage trials on its experimental COVID-19 vaccine later this year. Product sales rose 7% to $6.52bn, ahead of analysts' average forecasts of $6.50bn.
Hikma Pharmaceuticals reports increasing FY guidance for Generics revenue to between $720-740m.
Sainsbury's announces it could cut 3,500 jobs in a restructuring of the business. They report retail sales +7.1%, digital sales +117% with statutory group sales -1.1%. A loss before tax of £137m, reflecting £438m of one-off costs associated with Argos store closures and other strategic changes. Underlying profit before tax (excluding one off costs) of £301m. Special dividend of 7.3p and interim dividend of 3.2p. FY underlying profit before tax expected to be at least 5% higher than last year.
Tate & Lyle report a 9% increase in food and beverage profit, whilst sucralose profit was 12% lower. They maintained their interim dividend at 8.8p per share.
Trainline reports a significant impact on rail passenger numbers from COVID-19 as H1 net ticket sales were 19% (£358m) and revenues 24% (£31m) of the equivalent period last year.
Autotrader
Aveva Group
Sainsbury
Trainline
Wincanton
Wizz Air
Astrazeneca
Howden Joinery
RSA insurance
Superdry
Hansard
None
Eurozone Retail Sales
BoE Interest Rate Decision
Fed Interest Rate Decision
FOMC Press Conference
US Initial Jobless Claims
UK 100:
BP
UK 250:
Ashmore Group
Softcat
GCP Infrastructure Investments
Greencoat UK Wind
VinaCapital Vietnam Opportunity Fund
Hipgnosis Songs Fund
Dechra Pharmaceuticals
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.